Endocarditis in systemic lupus erythematosus
Methodology & AI Transparency ⓘ
Endocarditis in systemic lupus erythematosus Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Endocarditis in systemic lupus erythematosus is an ICD-10-CM indexed diagnosis (M32.11) within Rheumatoid Arthritis, Lupus & Autoimmune.
- 2 Real-world patient consensus: Mapped to Rheumatoid Arthritis, Lupus & Autoimmune under ICD-10-CM M32.11 for Endocarditis in systemic lupus erythematosus clinical workups.
- 3 Typical cash cost range: Primary evaluation for Endocarditis in systemic lupus erythematosus incorporates musculoskeletal ultrasound/MRI synovitis in Endocarditis in systemic lupus erythematosus (M32.11: grading) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Endocarditis in systemic lupus erythematosus: maintaining ANA, RF, Anti-CCP in Endocarditis in systemic lupus erythematosus (M32.11: & Complement C3/C4) within Disease-activity remission targets (M32.11).
Ask our AI Specialists anything about Endocarditis in systemic lupus erythematosus
What Is Endocarditis in systemic lupus erythematosus?
Endocarditis in systemic lupus erythematosus is an ICD-10-CM indexed diagnosis (M32.11) within Rheumatoid Arthritis, Lupus & Autoimmune. Clinical evaluation centers on musculoskeletal ultrasound/MRI synovitis in Endocarditis in systemic lupus erythematosus (M32.11: grading) alongside serial ANA, RF, Anti-CCP in Endocarditis in systemic lupus erythematosus (M32.11: & Complement C3/C4) tracking (Disease-activity remission targets (M32.11)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Endocarditis in systemic lupus erythematosus (code M32.11) is synovial pannus formation [Endocarditis in systemic lupus erythematosus M32.11], which Rheumatoid Arthritis, Lupus & Autoimmune clinicians address while surveilling ANA, RF, Anti-CCP in Endocarditis in systemic lupus erythematosus (M32.11: & Complement C3/C4) (Disease-activity remission targets (M32.11)).
Common Symptoms & Clinical Signs
- • Presentation of Endocarditis in systemic lupus erythematosus (M32.11): systemic inflammatory fatigue, in Endocarditis in systemic lupus erythematosus (M32.11: low-grade fevers, dry)
- • Secondary Endocarditis in systemic lupus erythematosus clinical sign: triphasic Raynaud color in Endocarditis in systemic lupus erythematosus (M32.11: changes in fingers)
- • Symptom flares in Endocarditis in systemic lupus erythematosus correlating with ANA, RF, Anti-CCP in Endocarditis in systemic lupus erythematosus (M32.11: & Complement C3/C4) deviation outside Disease-activity remission targets (M32.11)
- • Functional autoimmune disease impact requiring musculoskeletal ultrasound/MRI synovitis in Endocarditis in systemic lupus erythematosus (M32.11: grading) evaluation (M32.11)
Endocarditis in systemic lupus erythematosus Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M32.11 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Rheumatoid Arthritis, Lupus & Autoimmune | NLM Clinical Tables |
| Diagnostic / Lab Marker: ANA, RF, Anti-CCP in Endocarditis in systemic lupus erythematosus (M32.11: & Complement C3/C4) | Disease-activity remission targets (M32.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, ALT & in Endocarditis in systemic lupus erythematosus (M32.11: Creatinine (DMARD safety)) | Within normal safety monitoring limits (M32.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & ESR [Endocarditis in systemic lupus erythematosus M32.11] | hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M32.11) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Endocarditis in systemic lupus erythematosus
Treatment selection for Endocarditis in systemic lupus erythematosus depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Endocarditis in systemic lupus erythematosus)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Disease activity and glucocorticoid tapering patterns in Japanese patients with In the Japanese subpopulation of the TULIP-2 trial, anifrolumab resulted in improvements in disease activity to those reported for the overall population, suggesting a beneficial effect for disease control. Modern rheumatology • 2025-04-08 • Phase III Randomized Trial | N = 24 | 88/100 | PMID 39801286 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term effectiveness of a novel intra-oral electro-stimulator for the LEONIDAS-1 results support progression to a phase III definitive randomised controlled trial of salivary electrostimulation in individuals with Sjogren's syndrome. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology • 2023-08-15 • Phase III Randomized Trial | N = 15 | 88/100 | PMID 37220073 ↗ |
Endocarditis in systemic lupus erythematosus Patient Community & “People Like Me” Threads
Filter Endocarditis in systemic lupus erythematosus community threads and patient logs by age, biological sex, dosage, and treatment duration.